Biovie Inc. · NASDAQ:BIVI
Biovie — Technical Presentation (November 2023)
13 slides from Biovie's technical presentation, Nov 29, 2023
Slide 1: NE3107 Alzheimer's Disease Phase 3 Topline Readout
Slide 2: Forward-looking statements
Forward-looking statements This presentation contains statements about BioVie's future expectations. plans, strategies and prospects which constitute forward-looking statements. These forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Refo
Slide 3: Overview
Overview + NE3107 appears to be biologically active * Cognitive, functional, biomarker efficacy signal suggest that NE3107: - Has a treatment advantage equal to or greater than results reported from clinical trials from approved monoclonal antibody treatments; - Associated with a benign safety profi
Slide 4: Trial Timeline and Enrollment
Trial Timeline and Enrollment + The company monitors blinded data to track safety and ensure timely data entry into the EDC + The Company started noticing unusual data patterns when enough patients completed the trial. Pentara (a leading AD biostatistics firm) reviewed the blinded data and found: Se
Slide 5: Safety Profile
Safety Profile E3107 Pigcebo Total NE3107 Placebo Total E3107 Pisceno Tote ae 25% i7e8 482% “iipeureuer Book te gee 244 00% 39 __2a%_Om% "19% Una wae lean Tak See 79% “Bie we tn ‘ob “3a “iax Coe ees ico nro ainstnghomone seated Tak 39K B.SK “Goodledate sohoginase abnormal 00K 39K 13K “heontnanae ‘05
Slide 6: Data From All Sites In One Geographic Area Had Data Unlike All Other Sites
Data From All Sites In One Geographic Area Had Data Unlike All Other Sites All Sites In Affected Geographic Area All Sites Oustide Affected Geographic Area nme ee
Slide 7: Baseline Characteristics of Per-Protocol Population
Baseline Characteristics of Per-Protocol Population Se ee N Age ~ Mean years (Standard Deviation) <Toyears >=10 Gender Male Female Rave Asian Black/African American Caucasian Mot Reported (CDR'SB - Mean ($0) ADAS-Cog12 - Mean (SD) [MMSE - Mean ($0) ADCSADL - Mean (SD) ADCOMS - Mean (SO) 2a 75.4(6.4)
Slide 8: Week Suggest NE3107 Advantage vs. Placebo is Comparable to or Better than Approved Medications
Week 30 Suggest NE3107 Advantage vs. Placebo is Comparable to or Better than Results Reported from Clinical Trials by Approved Medications Change from baseline |__| Placebo Decline NE3107 NE3407 vs. Placebo | Comparator (48 mos) CDR-SB +1.39 +0.44 (lower is improvement (p=0.0125; n=26) (p=0.4522; n=
Slide 9: NE3107-treated Patients' Changes in CDR-SB Appears Correlated with Key Biomarkers
NE3107-treated Patients’ Changes in CDR-SB Appears Correlated with Key Biomarkers TNFa Phospho-Tau ABy2 / ABso 065. 105, 0.03. 5 5 * * ‘Slope = -0.239 ose «i os . oy 002 R=-0.230; p= 0.260 gle” © e 8 * egteet & . § 0242 § 0045. . -- 3 001 le . z 2 . . 2 le 200 = os. . 3} 0.00 | a re . Slope = 0.077
Slide 10: NE3107 Appears to Decrease the Neuroinflammatory Processes that Link Nf-L and GFAP
NE3107 Appears to Decrease the Neuroinflammatory Processes that Link Nf-L and GFAP to Cognitive Decline Placebo NE31O7 80 405 Slope = 3.44 . Slope =.0.035 60 R=0.610;p=0.002 204 R=-0.009;p= 0.968 S ° R404 e z § . g J a . z 2 £2. . = 3 3 3 NE3107 ‘Slope = 1.61 2 a . . too R= 0.009: p ao 8 ti « CS aL
Slide 11: NE3107-treated Patients Experienced Significant "Age Deceleration"
NE3107-treated Patients Experienced Significant “Age Deceleration” in a Manner Correlated to Cognitive and Functional Improvements Age Deceleration* is used by longevity researchers? to measure the difference between a person's 10 iological age and the actual chronological age. Placebo NE3107 Slope
Slide 12: Recap
Recap + NE3107 appears to be biologically active * Cognitive, functional, biomarker efficacy signal suggest that NE3107: - Has a treatment advantage equal to or greater than results reported from clinical trials from approved monoclonal antibody treatments; - Associated with a benign safety profile
Slide 13: Thank You